Objective: This study compared the clinicopathological features and survival of metastatic
prostate cancer (mPCa) after stratification by age and non-bone-related metastasis to …

Simple Summary In randomized trials, both chemotherapy and androgen-receptor signaling
inhibitors provided significant survival benefits in patients with metastatic prostate cancer …

Background An older age at the diagnosis of prostate cancer has been linked to worse
prostate cancer–specific survival (PCSS). However, these studies were conducted before …

To identify the clinical features and independent predictors of survival in older patients with
bone metastasis from prostate cancer (PCa). We retrospectively analysed 205 older patients …

Background Patients with prostate cancer is commonly diagnosed with bone metastases.
With the growing use of prostate-specific antigen testing, the frequency of prostate cancer …

Prostate cancer (PCa) survival markedly decreases with the occurrence of distant
metastasis, and treatment decisions can be influenced by metastasis site, and affect patient …

BACKGROUND In non‐castrate prostate cancer (PCa), the prognostic value of the number
of metastases on prostate cancer‐specific survival (PCSS) is not well studied. METHODS …

Introduction Metastatic prostate cancer (MPC) prognosis is variable. Few population-based
studies have examined the impact of particular visceral metastatic sites on MPC survival …

Background Bone is a preferential site for prostate cancer (PCa) metastasis. However, sites
of synchronous distant metastases in PCa patients with bone metastases at initial diagnosis …

Background The present of metastases is a poor prognostic factor in prostate cancer, but the
prognostic impact of different distant metastases pattern is unclear. The aim of this study is to …